Navigation Links
Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
Date:11/28/2008

WAYNE, Pa., Nov. 28 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on November 21, 2008, it received a letter from Nasdaq stating that since it had not yet filed its 10-Q for the quarterly period ended September 30, 2008 as of the date of the letter, it was no longer in compliance with the rules for continued listing according to Marketplace Rule 4310(c)(14).

The Nasdaq letter advised that Encorium had 60 calendar days from the date of the letter to submit a plan to regain compliance. Encorium filed its Form 10-Q for the quarterly period ended September 30, 2008 on Wednesday, November 26, 2008 and has notified Nasdaq of its filing. As a result, the Company anticipates it will receive notice from Nasdaq that it is currently in compliance with Nasdaq Marketplace Rule 4310(c)(14).

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health an
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... May 20, 2015 This year has ... for lawns. US Patented Pearl’s Premium Ultra Low ... around the country that are coming out of record ... a number of major global concerns related to water, ... grass – the alternative to the standard, water-wasting, chemical-treated ...
(Date:5/20/2015)... The global genotyping market is expected to grow at ... 2015 to 2020 to reach $17.0billion in 2020. Genotyping ... development process and to provide personalized therapy, factors that ... by key manufacturers to offer advanced and innovative products ... 113 market data tables & 37 figures spread through ...
(Date:5/20/2015)... 2015  Marc Tessier-Lavigne, president of The Rockefeller ... million from The Marie-Josée and Henry R. Kravis ... that will be the centerpiece of the University,s ... R. Kravis Research Building, two stories high, will ... three city blocks following the shoreline of the ...
(Date:5/20/2015)... 20, 2015  Resolution Bioscience announced today the successful ... TM , a blood-based liquid biopsy for an ALK-gene ... (NSCLC), the most common form of this cancer. Researchers ... patients to personalized therapies and direct them into clinical ... Department of Health, the CLIA authority in ...
Breaking Biology Technology:Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2
... March 18 Johnson & Johnson,Pharmaceutical Research ... received an approvable letter from the U.S. ... Drug Application (NDA) for,ceftobiprole for the treatment ... diabetic foot infections., J&JPRD, along with ...
... 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ... U.S. Patent 7,344,711 entitled "Use of Adenoviruses Mutated ... describe methods of treating,cancer using adenoviruses that are ... an activated Ras pathway., "This patent expands ...
... REDWOOD CITY, Calif., March 18 Ingenuity ... life science researchers, has,announced that they have ... GlaxoSmithKline for access to Ingenuity Pathways Analysis,(IPA) ... provide enterprise-wide,IPA access to researchers for rapid ...
Cached Biology Technology:FDA Issues Approvable Letter for Ceftobiprole for Treatment of Complicated Skin Infections 2Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent 2Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline 2
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS delegation ... had a strong showing at AUVSI,s Unmanned 2015 conference ... of Ohio,s UAS industry met with ... from all points along the UAS ecosystem. ... (DDC) Vice President for Aerospace Rich Knoll . "If ...
(Date:5/8/2015)... JOSE, Calif. , May 8, 2015 Synaptics ... interface solutions, today announced that members of the executive management ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Waterfront Hotel in Boston, MA ... May 27, 2015 Time: 2:45pm ET Location: The New York ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... Houston as a result of chemical pollution produced by manufacturing ... to a new study. But the new findings ... -- come with a catch, says a team of scientists ... CIRES, a joint institute of the University of Colorado at ...
... PARK, Md. - The University of Maryland, in partnership ... Maryland Baltimore County, has received a $7.9 million federal ... Resonance (NMR) magnet that will help researchers unravel the ... cancer, AIDS and other diseases. The grant is ...
... are reporting this week new study results they say provide ... from bone marrow for patients suffering from acute lung injury, ... intensive care units. Led by Drs. Michael A. Matthay ... the University of California, San Francisco, the team writes in ...
Cached Biology News:Texas petrochemical emissions down, but still underestimated, says study 2University of Maryland partnership receives $7.9M from NIH for superconducting research magnet 2University of Maryland partnership receives $7.9M from NIH for superconducting research magnet 3Using bone marrow stem cells to treat critically ill patients on verge of respiratory failure 2Using bone marrow stem cells to treat critically ill patients on verge of respiratory failure 3
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
Biology Products: